Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Pick the Right Toothpaste for Your Dental Requirements - 2Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- 3EU health regulator urges immediate vaccinations amid early surge in flu cases
- 4Most loved Road Food: Which One Prevails upon You?
- 5Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- ‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- The Effect of Online Organizations on Society: Beating the Difficulties
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- Vote In favor of Your Number one Game Control center
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
